Transglutaminases are a family of Ca2+-dependent enzymes which catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of glutaminyl residues of a protein/peptide substrate to lysyl residues of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted/cross-linked adducts) or –OH groups (to form ester linkages). In absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue. Transglutaminase activity has been suggested to be involved in molecular mechanisms responsible for both physiological and pathological processes. In particular, transglutaminase activity has been shown to be responsible for human autoimmune diseases, and Celiac Disease is just one of them. Interestingly, neurodegenerative diseases, such as Alzheimer’s Disease, Parkinson’s Disease, supranuclear palsy, Huntington’s Disease and other polyglutamine diseases, are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains. In this special issue we will focus on the possible molecular mechanisms by which these enzymes could be responsible for human diseases and the possible use of transglutaminase inhibitors for patients with diseases characterized by aberrant transglutaminase activity.
Professor Vittorio GentileGuest Editor
Submission Deadline: 15 October 2018
Manuscripts should be submitted online through ScholarOne Manuscripts for Med One © Clarivate Analytics. Please visit Guide for Authors before submitting a manuscript. Authors are encouraged to submit a paper as soon as it is ready and don’t need to wait until the deadline. Submissions will be sent to peer-review in order of arrival. Accepted papers will be published continuously in Med One and then gathered together on the special issue webpage. We welcome Research articles, Review papers and Short Communications. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
1. Elisabetta V. Edwards
Nottingham Trent University, Nottingham, UK
2. Marcela V. Karpuj
Bar Ilan University, Ramat Gan, Israel
3. Said EL Alaoui
Covalab, Villeurbanne, France
4. Siiri Iismaa
Victor Chang Cardiac Research Institute, Darlinghurst, Australia
5. Salvatore Condello
Northwestern University, Evanston, IL, USA
6. Aaron Lerner
Technion - Israel Institute of Technology, Israel / Aesku.Kipp Institute, Germany
7. Richard J Ablin
The University of Arizona Cancer Center, Tucson, AZ, USA
8. Nancy A. Muma
University of Kansas School of Pharmacy, Lawrence, KS, USA
9. Philip Bonner
Nottingham Trent University, Nottingham, United Kingdom
10. Richard Cerione
Cornell University, Ithaca, NY, USA
Virtual Special Issue (VSI) is a collection of papers centered around a specific topic, led by an expert (Guest Editor) in the field. Virtual Special Issues are an important component of our journal and cover current hot topics within the scope of the journal.
All papers belonging to a Virtual Special Issue will be gathered together on a single webpage. They are published in the regular issues of the journal as soon as publishable, and labeled as belonging to the Virtual Special Issue. A link from each paper will take you to the Virtual Special Issue website.
Submissions to Virtual Special Issues will undergo the same rigorous peer-review process as regular papers submitted to the journal.
Department of Precision Medicine, CIRN - Interuniversity Center of Neuroscience Researches, University of Campania "Luigi Vanvitelli"